Similar Risk of Kidney Failure among Patients with Blinding Diseases Who Receive Ranibizumab, Aflibercept, and Bevacizumab

• DOI: 10.1016/j.oret.2024.03.014
• Publication Date: 2024-03-21T00:45:53Z
• Authors: Cindy X. Cai; Akihiko Nishimura; Mary G. Bowring; Erik Westlund; Diep Tran; Jia H. Ng; Paul Nagy; Michael Cook; Jody-Ann McLeggon; Scott L. DuVall; Michael E. Matheny; Asieh Golozar; Anna Ostropolets; Evan Minty; Priya Desai; Fan Bu; Brian Toy; Michelle Hribar; Thomas Falconer; Linying Zhang; Laurence Lawrence...; Michael V. Boland; Kerry Goetz; Nathan Hall; Azza Shoaibi; Jenna Reps; Anthony G. Sena; Clair Blacketer; Joel Swerdel; Kenar D. Jhaveri; Edward Lee; Zachary Gilbert; Scott L. Zeger; Deidra C. Crews; Marc A. Suchard; George Hripcsak; Patrick B. Ryan